Palmar-plantar Erythrodysesthesia Clinical Trial
Official title:
Topical Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Associated With Capecitabine
The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00992706 -
F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05939726 -
Efficacy and Safety of Moisturising Cream With or Without Vitamin E and Urea Cream in Palmar-plantar Erythrodysesthesia
|
N/A | |
| Terminated |
NCT00486213 -
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
|
Phase 3 | |
| Completed |
NCT02625415 -
The Topical Application of Vitamin B6 in Palmar-Plantar Erythrodysesthesia
|
N/A | |
| Active, not recruiting |
NCT00559858 -
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer
|
Phase 3 | |
| Terminated |
NCT00751101 -
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT01100463 -
Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome
|
Phase 1/Phase 2 |